Latest news

• NICE knocks-back Shire's pancreatic cancer drug Onivyde

  NICE has ruled that Shire’s pancreatic cancer drug Onivyde (pegylated liposomal irinotecan) is not a cost-effective use of NHS resources. ... NICE said in a statement: “Although this analysis was subject to considerable uncertainty, the committee was

• Ipsen buys cancer business from stripped down Merrimack

  The deal includes Onivyde (liposomal irinotecan) and Merrimack's generic version of Doxil (liposomal doxorubicin), as well as the manufacturing and commercial operations supporting the two products.

• Shire wins EU licence for pancreatic cancer drug Onivyde

  Authorised as a second-line combination therapy, Onivyde (pegylated liposomal irinotecan hydrochloride trihydrate) will be administered with 5-fluorouracil (5-FU) and leucovorin (LV) in adult patients who have progressed following

• HIV prevention pill heads July CHMP recommendations

  The CHMP also gave a positive opinion for Shire's Onivyde (pegylated irinotecan liposomal formulation) for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin,